J2779 HCPCS Level II Code: Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
Medicare Coverage & Payment
- Medicare coverage: Carrier judgment (CMS coverage code C)
- Payment category: Drugs (pricing indicator 51)
- BETOS: O1E — Other drugs
- Last CMS action effective: July 1, 2022
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Official Registry Overview & Definition
Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg is a HCPCS Level II code (J2779). CMS assigns coverage code C — Carrier judgment. Short description: Inj, susvimo 0.1 mg.
Nearest Codes in This Family
Official HCPCS Level II classifications closest to J2779 in its code family, with their registry titles.
- J2760 — Injection, phentolamine mesylate, up to 5 mg
- J2765 — Injection, metoclopramide hcl, up to 10 mg
- J2770 — Injection, quinupristin/dalfopristin, 500 mg (150/350)
- J2777 — Injection, faricimab-svoa, 0.1 mg
- J2778 — Injection, ranibizumab, 0.1 mg
- J2780 — Injection, ranitidine hydrochloride, 25 mg
- J2781 — Injection, pegcetacoplan, intravitreal, 1 mg
- J2782 — Injection, avacincaptad pegol, 0.1 mg
- J2783 — Injection, rasburicase, 0.5 mg
- J2785 — Injection, regadenoson, 0.1 mg